UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study
UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study
复制标题
DOI：
10.1186/s12885-020-07225-1
复制
发表时间：
2020-08-05
期刊：
影响因子：
3.8
通讯作者：
Mandai, Masaki
中科院分区：
文献类型：
--
作者：
Matsuoka, Hideki;Murakami, Ryusuke;Mandai, Masaki
背景尿苷二磷酸葡萄糖醛酸转移酶 1 家族多肽 A1 (UGT1A1) 是伊立替康化疗副作用的预测生物标志物，可减少含有 UGT1A1 多态性的肿瘤体积。我们的目的是确定 UGT1A1 多态性是否可以预测接受伊立替康化疗的局部宫颈癌患者的无进展生存期。方法我们回顾性分析了 2010 年至 2015 年间在同一机构治疗的 51 例宫颈癌患者的数据。所有患者均诊断为 2009 年国际妇产科联合会 (FIGO) IB1、IB2、IIA 或 IIB 期鳞状细胞癌，均接受过根治性子宫切除术，并接受伊立替康化疗作为新辅助和/或辅助治疗。使用 UGT1A1 测试检查所有患者的伊立替康副作用。考虑FIGO分期、年龄、UGT1A1状态和转移淋巴结数量进行条件推理树和生存分析，以确定与无进展生存相关的主要因素。结果树结构生存模型确定了与无进展生存相关的高复发风险因素。最相关的因素是 >= 2 个转移淋巴结 (p=0.004)。第二个最相关的因素是 UGT1A1 基因型 (p=0.024)。在患者中
BackgroundUridine diphosphate glucuronosyltransferase 1 family polypeptide A1 (UGT1A1) is a predictive biomarker for the side-effects of irinotecan chemotherapy, which reduces the volume of tumors harboring UGT1A1 polymorphisms. We aimed to determine whether UGT1A1 polymorphisms can predict progression-free survival in patients with local cervical cancer treated with irinotecan chemotherapy.MethodsWe retrospectively analyzed the data of 51 patients with cervical cancer treated at a single institution between 2010 and 2015. All patients were diagnosed with 2009 International Federation of Gynecology and Obstetrics (FIGO) stage IB1, IB2, IIA, or IIB squamous cell carcinoma, underwent radical hysterectomy, and received irinotecan chemotherapy as neoadjuvant and/or adjuvant treatment. All patients were examined for irinotecan side effects using UGT1A1 tests. Conditional inference tree and survival analyses were performed considering the FIGO stage, age, the UGT1A1 status, and the number of metastatic lymph nodes to determine primary factors associated with progression-free survival.ResultsThe tree-structured survival model determined high recurrence-risk factors related to progression-free survival. The most relevant factor was >= 2 metastatic lymph nodes (p=0.004). The second most relevant factor was UGT1A1 genotype (p=0.024). Among patients with